NeuroSense Therapeutics Ltd.
NRSNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | downgrade | Buy →Neutral | Nov 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 28, 2026 |
| D. Boral Capital | maintain | Buy | Apr 8, 2026 |
| D. Boral Capital | maintain | Buy | Mar 25, 2026 |
| D. Boral Capital | maintain | Buy | Mar 17, 2026 |
| D. Boral Capital | maintain | Buy | Mar 9, 2026 |
| D. Boral Capital | maintain | Buy | Dec 22, 2025 |
| D. Boral Capital | maintain | Buy | Nov 24, 2025 |
| D. Boral Capital | maintain | Buy | Aug 15, 2025 |
| D. Boral Capital | maintain | Buy | Jul 10, 2025 |
| Maxim Group | downgrade | Buy →Hold | Dec 16, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 25, 2026 | $-2.06 | $-3.90 | — | $535.6K |
| Jun 30, 2026 | $-3.90 | $-3.90 | — | $267.8K |
| Mar 31, 2026 | $-0.23 | $-0.07 | — | — |
| Dec 17, 2025 | $-2.60 | $-0.87 | — | — |
| Aug 1, 2025 | $-0.14 | $-0.22 | — | — |
| Apr 7, 2025 | $-0.06 | $-0.10 | — | — |
| Apr 4, 2025 | $-1.66 | — | — | — |
| Dec 18, 2024 | $-0.11 | $-3.20 | — | — |
News
Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline Submission would be PrimeC's first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS CAMBRIDGE, Mass., Nov. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON CAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE) Positions PrimeC for potential expansion beyond ALS into an indication affecting millions worldwide, with no approved disease-modifying therapy Filing supports opportunities for research partnerships CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027 CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass., Sept. 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.
Company presentation on Tuesday, September 15 at 4:30 p.m. ET Management will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass.
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mass.
CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.